Regional Medical Scientific Director

Senator questions Merck over patent strategy for blockbuster cancer drug Keytruda. by Politixia about 5 hours ago 130 Views Announcement A U.S. senator is pressing pharmaceutical giant Merck over its patenting and pricing practices for the blockbuster cancer drug Keytruda, escalating congressional scrutiny of industry strategies that can delay lower-cost rivals from reaching the market. Announcement Sen. Maggie Hassan (D-N.H.), ranking member of the Senate Finance Subcommittee on Health Care, said that Merck and other drug companies often file excessive patents to extend their monopolies and keep more affordable versions of their pricey drugs out of reach. In a letter to Merck CEO Robert Davis, the lawmaker asked the company to detail patent actions connected to both the Keytruda intravenous version, which has been on the market for over a decade, and its new injectable version of the drug, which launched last year. "I continue to have serious concerns about how Merck's anti-competitive practices have boosted profits at the expense of patients," Hassan wrote in her letter, sent this week. She added she has noted in previous years how "these kinds of patent gimmicks have allowed Merck to delay other companies from selling lower cost versions of this medication, all while raising the price of Keytruda in the U.S. year after year." Hassan cited a finding from the International Consortium of Investigative Journalists' recent Cancer Calculus investigation, which showed that Merck's new injectable version of Keytruda "could help Merck generate billions of dollars and delay competition into the 2030s." ICIJ's Cancer Calculus revealed how Merck uses pricing, patent and dosing strategies to turn the life-saving medicine into one of the world's best selling drugs - while leaving many patients around the world struggling to access it. The company and other cancer research businesses filed 1,212 patent applications in 53 jurisdictions, which can extend Keytruda's control of the market. Keytruda carried high list prices that have strained the budgets of even wealthy nations, ranging from more than $80,000 for a year of treatment in Germany, $93,000 in Lebanon, and $130,000 in Colombia, to as much as $208,000 in the U.S. The exorbitant prices and desperate patients have fueled a counterfeit market, with incidents of fake Keytruda surfacing in public hospitals in Mexico. High costs and restrictive insurance protocols have also forced many patients into long, grueling legal battles just to access the drug. A Merck spokesperson did not respond to a request for comment sent by ICIJ on Thursday. Earlier this year, the company told ICIJ and its global media partners that it is a "common myth" that companies use many patents to block competition, and said more patents do not determine when generics or biosimilars enter the market. ICIJ found that Merck's secondary patents could potentially extend Keytruda's exclusivity in the U.S. until at least 2042, which may delay cheaper alternatives for hundreds of thousands of patients over the next 15 years. Keytruda's primary patents are set to expire in 2028. Announcement Hassan's letter included 10 questions the senator seeks answers to and asked Davis to respond by no later than July 20. She asked why Merck is using a large number of secondary patents for Keytruda and how it justifies that strategy; whether this approach delays biosimilar competition and keeps prices high for patients, and what Merck is doing to make sure lower-cost alternatives can reach patients once the main patents expire. The letter also asks whether the shift from intravenous Keytruda to an injectable version could be used to extend market exclusivity and delay lower-cost competition. In her letter, Hassan describes an exchange with Davis during a 2024 Senate hearing, in which she pressed him about the tactics that have allowed Merck to "delay other companies from selling lower cost versions" of Keytruda while raising the price of the drug annually. At the time, Davis said the system needs both patent protection and a strong biosimilar and generic market, and that he would not block an intravenous biosimilar of Keytruda after key patents expire. "Despite these statements, existing patents for [intravenous] Keytruda and a new form of the medication may help block or minimize competition from biosimilars for years," Hassan wrote. Announcement The inquiry is part of a broader congressional push to address prescription drug pricing, patent disputes, and alleged "product hopping" strategies that some lawmakers say can delay cheaper alternatives from reaching patients. One of the bills being considered is the Medication Affordability and Patent Integrity Act, sponsored by Hassan and Sen. Josh Hawley (R-MO). The proposed law, which aims to reform patent review and facilitate the entry of generics and biosimilars to the market, was advanced by the Senate Committee on Health, Education, Labor, and Pensions in June. Announcement

Merck cements Life Science leadership with $11.3B Bio-Techne acquisition. Friday, June 26, 2026 The life science tools market is heating up with Merck's blockbuster $11.3 billion acquisition of Bio-Techne. This strategic move is designed to cement the company's leadership in a rapidly growing sector and signals a major consolidation trend that is actively reshaping the industry for competitors and investors alike. Audio Brief (2:45 listen) The life science tools market, the critical "picks and shovels" infrastructure for the biopharmaceutical revolution, is witnessing a significant consolidation wave. In a landscape where scale and portfolio breadth are paramount, major players are aggressively pursuing M&A to secure long-term growth and competitive advantage. The latest blockbuster move comes from Merck, which has announced a definitive agreement to acquire Bio-Techne for an enterprise value of approximately $11.3 billion. This transaction is more than a simple expansion; it's a calculated maneuver to fortify Merck's leadership in high-growth areas like cell and gene therapy, proteomics, and diagnostics, signaling an intensified competitive environment for peers like Thermo Fisher Scientific and Danaher. A strategic bolt-on to cement leadership. Merck's acquisition of Bio-Techne is a clear reflection of its strategy to build an end-to-end offering for the biopharma industry through its Life Science business sector. While Merck already possesses a formidable portfolio, particularly in bioprocessing (the manufacturing of biologic drugs), the addition of Bio-Techne provides critical assets in the upstream research and discovery and quality control phases. * Strategic Rationale: The primary driver for this deal is the complementary nature of the two portfolios. Bio-Techne is a market leader in high-quality proteins, antibodies, and immunoassays - essential, high-margin consumables used extensively in academic research, drug discovery, and clinical diagnostics. These products fit seamlessly into Merck's existing research solutions business, creating significant cross-selling opportunities. By integrating Bio-Techne's reagent and small instrument capabilities, Merck can offer its customers a more comprehensive workflow solution, from initial discovery to final manufacturing. * Valuation Context: The US$73 per share cash offer, representing an $11.3 billion enterprise value, reflects the high strategic value placed on premium life science assets. Companies like Bio-Techne are highly attractive due to their strong brand recognition, intellectual property, and "razor-and-blade" business model, which generates predictable, recurring revenue from consumables. While the implied valuation multiple is substantial, it is in line with recent transactions in the sector, where acquirers are willing to pay a premium for assets that offer both market leadership and exposure to the fastest-growing segments of healthcare innovation. * Market Positioning: This deal significantly strengthens Merck's position as one of the top-tier suppliers to the global life science industry. It narrows the gap with larger, more diversified competitors and enhances Merck's "one-stop-shop" appeal. For large pharmaceutical and emerging biotech clients, the ability to source a wider range of critical reagents and instruments from a single, trusted partner simplifies procurement and can de-risk their supply chains - a crucial consideration in the post-pandemic era. Reshaping the competitive landscape. Merck's move is set to send ripples across the life science tools sector, forcing competitors to reassess their own strategic positions. The industry has long been characterized by a race for scale, and this acquisition raises the stakes considerably. For decades, the market has been dominated by a handful of large consolidators. This transaction reaffirms that aggressive M&A remains the primary tool for growth and market share capture. Competitors will now face a more formidable Merck, armed with a deeper portfolio in proteomics and diagnostics. This will likely spur further consolidation as other players look to fill gaps in their own offerings or acquire new technologies to stay competitive. The acquisition particularly amplifies Merck's capabilities in the burgeoning cell and gene therapy (CGT) space. Bio-Techne provides critical analytical and quality control tools used to characterize and release these complex therapies. By combining these with its own viral vector manufacturing solutions, Merck can offer a more integrated and compelling value proposition to CGT developers, a market segment poised for exponential growth. This strategic depth will be difficult for smaller, more specialized players to replicate. The path forward. The successful integration of Bio-Techne will be the immediate focus for Merck's leadership. Capturing the promised revenue and cost synergies will require a deft hand in merging distinct corporate cultures and aligning complex product roadmaps and sales channels. However, the strategic logic underpinning the deal appears sound and compelling. This acquisition is a bold statement of intent from Merck. It underscores a commitment to leading the life science tools market not just in established areas like bioprocessing but across the entire research and development continuum. For the industry at large, it signals that the era of transformative M&A is far from over. As the pace of biomedical innovation continues to accelerate, the race to supply the scientists and manufacturers on the front lines will only grow more intense. Analyze your own CIM. Upload a CIM and get financials, risks, and valuation in seconds.

Merck partners with Saturnus Bio to advance precision treatments for rare genetic Heart Diseases. Merck and Saturnus Bio launch strategic research collaboration. Merck has announced a new research-stage collaboration with Saturnus Bio, a biotechnology company founded by Versant Ventures, to develop innovative treatments for rare genetic cardiomyopathies. The partnership marks an important step in Merck's strategy to expand its presence in cardiovascular medicine while focusing on precision therapies for patients with rare diseases that currently have limited treatment options. The collaboration will help establish a foundational portfolio targeting inherited heart conditions caused by specific genetic mutations. Focus on rare genetic cardiomyopathies. Rare genetic cardiomyopathies are heart muscle diseases caused by inherited genetic changes. These conditions can affect how the heart pumps blood and may lead to serious complications, including heart failure, irregular heart rhythms, and sudden cardiac events. Despite advances in cardiovascular medicine, there are currently no approved therapies that directly target many of the underlying genetic causes of these diseases. Merck and Saturnus Bio aim to address this gap by developing treatments designed specifically for patients with genetically defined forms of cardiomyopathy. Saturnus Bio brings precision cardiology expertise. Saturnus Bio is focused on next-generation precision cardiology and uses targeted gene modulation technologies to develop therapies for rare monogenic heart diseases. The company's approach is built around identifying specific genetic drivers of disease and designing treatments that address those underlying causes. Through the partnership, Merck will gain access to Saturnus Bio's scientific expertise and research platform while supporting the development of new drug candidates for rare cardiovascular conditions. Merck strengthens its precision medicine strategy. According to Merck, the collaboration supports the company's broader effort to expand into precision medicine-driven indications. David Weinreich, MD, Head of Research and Development and Chief Medical Officer for Merck's Healthcare business, said the partnership is intended to accelerate the development of innovative therapies for patients affected by genetic cardiomyopathies. He noted that combining Saturnus Bio's specialized expertise with Merck's capabilities in advanced therapeutic technologies could help speed up the development of targeted treatment options for patients with limited alternatives. The collaboration also allows Merck to explore new opportunities within cardiovascular medicine while building on its existing scientific capabilities. Deal Includes Funding and Future Acquisition Rights The agreement follows a build-to-buy structure, giving Merck the opportunity to support Saturnus Bio's early development efforts while retaining the option for a future acquisition. Under the terms of the deal, Merck will provide an upfront payment of $50 million to fund Saturnus Bio's research activities. The company will also receive a minority equity stake in Saturnus Bio. In addition, the agreement includes success-based preclinical milestone payments tied to the advancement of research programs. Merck has secured exclusive rights to acquire Saturnus Bio in the future through a predetermined option arrangement, along with additional earnout payments linked to development success. Versant Ventures Sees Opportunity in Emerging Disease Areas Rick Dewey, MD, Entrepreneur-in-Residence at Versant Ventures and Chief Executive Officer of Saturnus Bio, said the collaboration reflects Versant's strategy of partnering with major pharmaceutical companies to build new treatment platforms in areas with high unmet medical need. He stated that the partnership positions Saturnus Bio to accelerate the development of its pipeline of first-in-class medicines for genetic cardiomyopathies. The collaboration also provides the resources needed to advance research programs aimed at addressing diseases that currently lack effective treatment options. Genetic Heart Diseases Represent an Untapped Opportunity For Merck, genetic cardiomyopathies represent a strategic entry point into a segment of cardiovascular medicine where significant unmet need remains. Because there are currently no approved therapies specifically targeting the genetic drivers of many cardiomyopathies, researchers see an opportunity to develop precision medicines that could potentially change the treatment landscape. By focusing on genetically defined patient populations, Merck hopes to reduce development risks through stronger biological understanding and more targeted clinical programs. Partnership Supports Merck's Long-Term Research Goals Merck stated that the collaboration aligns with its broader strategy of using advanced technologies, data science, and precision medicine approaches to improve research productivity and pipeline development. The company continues to focus on identifying diseases where strong preclinical and early clinical evidence can support more efficient drug development. Through its partnership with Saturnus Bio, Merck is looking to advance a new generation of targeted therapies for rare cardiovascular diseases while expanding its capabilities in precision medicine and genetic disease research.